Press Releases Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 12/12/2025 GMT			5-day change	1st Jan Change
321.15 ^DKK	+0.45%		+3.73%	-48.55%

12-12	Sector Update: Health Care Stocks Advance Late Afternoon	MT
12-12	Sector Update: Health Care Stocks Edge Higher Friday Afternoon	MT

Press Releases

Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss	12-12	GL
Novo Nordisk A/S : Rules of Procedure for the Board of Directors ( rules of procedure 2025 )	12-12	PU
Novo Nordisk A/S : Charter of the Chair Committee of the Board of Directors ( charter chair committee 2025 )	12-12	PU
Novo Nordisk A/S : Charter of the Audit Committee of the Board of Directors ( charter audit committee 2025 )	12-12	PU
Novo Nordisk A/S : Charter of the People & Governance Committee of the Board of Directors ( charter of people and governance committee 2025 )	12-12	PU
Novo Nordisk A/S : Charter of the Remuneration Committee of the Board of Directors ( charter remuneration committee 2025 )	12-12	PU
Novo Nordisk A/S : Charter of the Research & Development Committee of the Board of Directors ( charter r and d committee 2025 )	12-12	PU
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 Reinforcing the Scientific Rationale for LX9851	12-11	AQ
Klaus Skovrup appointed CFO of Napatech	12-11	AQ
Novo Nordisk has completed its acquisition of Akero Therapeutics	12-09	GL
GLP-1 Agonists Market: Driving Innovation and Growth in Metabolic and Cardiovascular Care	12-08	AQ
Novo Nordisk A/S : Minutes and voting results from Extraordinary General Meeting 2025 ( novo nordisk egm 2025 minutes )	11-28	PU
Novo Nordisk A/S : Presentation from Extraordinary General Meeting 2025 ( egm presentation 2025 )	11-28	PU
Alzheimer's Phase III miss signals GLP-1RA combination therapy potential	11-25	AQ
Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes	11-25	GL
Novo Nordisk A/S, Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression	11-25	AQ
Federal Jury Clears Novo Nordisk in False Claims Act Case that Included Testimony by Analysis Group Affiliate Anupam Jena	11-25	AQ
Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression	11-24	GL
US stocks open higher at the start of a holiday-shortened week	11-24	AQ
Novo Nordisk Secures Trial Victory In Off Label Promotion, Kickback Case	11-19	AQ
Chromologics raises €7 million to bring its natural colour ingredients closer to market	11-18	AQ
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons	11-17	GL
Novo cuts Wegovy prices, but doctors still see cost challenges for patients	11-17	AQ
Resolutions from the Extraordinary General Meeting of Novo Nordisk A/S	11-14	GL
Novo Nordisk A/S: Candidate for the Board of Directors will not seek election	11-13	GL